
    
      OBJECTIVES: I. Determine the activity of ZD 1839 in patients with metastatic or recurrent
      squamous cell carcinoma of the head and neck. II. Determine the effectiveness of this regimen
      in these patients. III. Determine the toxicity of this regimen in these patients.

      OUTLINE: This is a multicenter study. Patients receive oral ZD 1839 once daily on days 1-28.
      Treatment repeats every 28 days in the absence of disease progression or unacceptable
      toxicity. Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 22-46 patients will be accrued for this study within 1-2 years.
    
  